South & Central America Custom Antibody Services Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The custom antibody services market in South and Central America is projected to grow significantly, reaching approximately USD 49.87 million by 2031, up from USD 23.73 million in 2023, with an estimated compound annual growth rate (CAGR) of 9.7% from 2023 to 2031.

Executive Summary and Market Analysis

The expansion of the custom antibody services market in South and Central America is primarily fueled by increased investments in biomedical research, a rise in chronic disease prevalence, and a growing demand for targeted therapies. Brazil and Argentina are becoming pivotal players in this market due to enhancements in research infrastructure and increased healthcare expenditures. Academic institutions and biotechnology companies are increasingly outsourcing antibody development to specialized service providers to expedite drug discovery and diagnostic processes. Despite facing challenges such as limited funding and regulatory obstacles, the market is expected to experience steady growth, supported by technological advancements and international collaborations.

Market Segmentation Analysis

The South and Central America custom antibody services market can be segmented based on product type, service type, application, disease indication, source, and end user:

Product Type: The market is divided into monoclonal, polyclonal, hybridoma, recombinant antibodies, and others. In 2023, monoclonal antibodies held the largest market share.
Service Type: This segment includes antibody discovery and development, antibody production services, and others, with antibody discovery and development leading in market share in 2023.
Application: The applications include immunohistochemistry, western blotting & immunoprecipitation (IP), ELISA, fluorescence-activated cell sorting, mass spectrometry, and others. ELISA was the dominant application in 2023.
Disease Indication: The market is segmented into oncology, infectious diseases, immunology, cardiovascular diseases, and others, with oncology being the largest segment in 2023.
Source: This includes chicken, rabbits, rats, guinea pigs, and mouse or humanized mice, with the latter holding the largest share in 2023. This segment further includes monoclonal antibody platforms, bispecific antibody discovery platforms, and others.
End User: The end users are categorized into the life sciences industry, pharmaceutical and biotech companies, academic and research institutes, and contract research organizations, with the life sciences industry leading in market share in 2023.

Market Outlook

Recombinant antibody engineering presents vast opportunities for drug developers and researchers to create specific molecules tailored for particular diseases. Many developers are leveraging AI technologies to predict and analyze potential therapeutics from antibody sequences, enhancing the efficiency of drug development. For example, Foundation Medicine utilizes next-generation sequencing technology to create genomic profiling assays that help match patients with targeted therapies and clinical trials. Similarly, the Medicines Discovery Catapult is employing in-silico methods to identify new cancer treatment molecules, showcasing the integration of AI in drug discovery.

Country Insights

The market comprises Brazil, Argentina, and other regions in South and Central America, with Brazil holding the largest market share in 2023. The aging population in Brazil is contributing to a rise in chronic diseases. According to the Pan American Health Organization, over 30 million Brazilians are aged 60 and above, a figure expected to rise to nearly 50 million by 2030. This demographic shift is associated with increased incidences of chronic conditions, making custom antibodies vital for targeted diagnostics and treatments.

Brazil has seen significant regulatory support for antibody research, with initiatives such as the authorization of Sorrento Therapeutics for clinical trials involving monoclonal antibodies for COVID-19. Additionally, GenScript's approval for a neutralization antibody detection kit and collaborations for developing biosimilars indicate a robust environment for biopharmaceutical research. These developments, along with ongoing improvements in healthcare infrastructure and diagnostic laboratories, are anticipated to further stimulate market growth.

Company Profiles

Key players in the custom antibody services market include Thermo Fisher Scientific Inc., Sino Biological Inc., GenScript Biotech Corporation, Biochain Incorporated, R&D Systems, Inc., Kaneka Eurogentec S.A., Fortis Life Sciences, Precision Antibody, Biocytogen Pharmaceuticals, Abgenex, Creative Biolabs, Agilent Technologies, Bioklone, and Scantibodies Laboratory, Inc. These companies are pursuing various strategies such as market expansion, product innovation, and mergers and acquisitions to enhance their offerings and increase market share.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America custom antibody services market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in South & Central America custom antibody services market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the custom antibody services market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution. Show more